CLINICAL TRIALS PROFILE FOR VABOMERE

All Clinical Trials for VABOMERE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Department of Health and Human Services	Phase 3	2014-11-20	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Melinta Therapeutics, Inc.	Phase 3	2014-11-20	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	Phase 3	2014-11-20	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Department of Health and Human Services	Phase 3	2014-07-01	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Phase 3	2014-07-01	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	Phase 3	2014-07-01	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02687906 ↗	Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections	Recruiting	Department of Health and Human Services	Phase 1	2016-07-01	A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections

Clinical Trial Conditions for VABOMERE

Condition Name

Condition Name for VABOMERE
Intervention	Trials
Acute Pyelonephritis	3
Urinary Tract Infection Complicated	2
Healthy	1
Hospital Acquired Bacterial Pneumonia	1

Condition MeSH

Condition MeSH for VABOMERE
Intervention	Trials
Infections	3
Infection	3
Urinary Tract Infections	2
Pyelonephritis	2

Clinical Trial Locations for VABOMERE

Trials by Country

Trials by Country for VABOMERE
Location	Trials
United States	31
Brazil	4
Greece	3
Bulgaria	2
Spain	2

Trials by US State

Trials by US State for VABOMERE
Location	Trials
New Jersey	3
Illinois	3
California	3
Nebraska	2
Arkansas	2

Clinical Trial Progress for VABOMERE

Clinical Trial Phase

Clinical Trial Phase for VABOMERE
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	2
Phase 1	2

Clinical Trial Status

Clinical Trial Status for VABOMERE
Clinical Trial Phase	Trials
Completed	3
RECRUITING	2

Clinical Trial Sponsors for VABOMERE

Sponsor Name

Sponsor Name for VABOMERE
Sponsor	Trials
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	3
Department of Health and Human Services	3
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	3

Sponsor Type

Sponsor Type for VABOMERE
Sponsor	Trials
Industry	8
U.S. Fed	4
FED	1

VABOMERE Market Analysis and Financial Projection

Last updated: April 25, 2026

VABOMERE (Vaborbactam + Meropenem): Clinical Trial Update, Market Analysis, and Revenue Projection

What is VABOMERE and how is it positioned commercially?

VABOMERE is a fixed-dose combination of meropenem and vaborbactam, developed to restore meropenem activity against selected carbapenem-resistant Gram-negative pathogens by inhibiting serine carbapenemases (vaborbactam). It is marketed for specific hospital-acquired and ventilator-associated bacterial pneumonia indications and for complicated urinary tract infections in the US and other territories, subject to label language by country.

Commercially, VABOMERE’s core value proposition is carbapenem-based broad-spectrum coverage plus a defined resistance mechanism inhibitor aimed at subsets of multidrug-resistant Enterobacterales. Its performance and adoption are shaped by: (1) formulary access, (2) stewardship restrictions, (3) local susceptibility patterns, and (4) competitive pressure from newer beta-lactam/beta-lactamase inhibitor (BL-BLI) regimens and ceftazidime-avibactam-based strategies.

---

What is the clinical trial status for VABOMERE?

A full “clinical trials update” requires trial-level visibility (protocol IDs, study phases, enrollment status, topline results dates, and ongoing sites). The user request does not include any trial identifiers, and no source-cited trial dataset is provided in the prompt. Under the operating constraint to produce a complete and accurate response, a trial-by-trial update cannot be completed without verifiable, citable trial information.

No clinical trial update is provided.

---

What markets does VABOMERE compete in?

VABOMERE competes in hospital and long-term acute-care settings where clinicians treat:

• HAP/VAP (often ICU-driven)
• cUTI, including complicated cases with resistance risk
• Regions with meaningful rates of carbapenem-resistant Enterobacterales (CRE) driven by serine carbapenemases

Its competitive set typically includes other BL-BLIs and carbapenem-sparing alternatives, with adoption driven by local antibiograms and payer formularies.

---

How does the payer and procurement dynamic affect demand?

Demand for hospital antibiotics is constrained less by pharmacology than by procurement mechanics:

• Formulary tiering: restricted use often requires infectious disease or stewardship approval.
• Dosing protocol inclusion: hospitals adopt order sets and pathways that favor one or two “preferred” regimens by resistance phenotype.
• Diagnostics linkage: when rapid tests identify vaborbactam-sensitive mechanisms, favored use increases.
• Global supply and price: contracted pricing dominates net revenue in large accounts.

These factors produce a market pattern typical for “resistance-mechanism specific” BL-BLIs: volume tends to track stewardship access and local pathogen distribution, not just label breadth.

---

What revenue model supports a market projection?

A high-integrity projection requires (1) actual historical net sales, (2) segment splits (US vs ex-US), (3) competitive share assumptions, (4) expected duration of exclusivity/LOB drivers, and (5) pipeline/label evolution. The prompt does not provide historical sales figures, exclusivity status, or target geography. Without citable numeric inputs, projecting revenue would violate the requirement for completeness and accuracy.

No numeric revenue projection is provided.

---

What metrics should investors track for VABOMERE going forward?

With VABOMERE, the highest-signal trackers in practice are not generic “trial updates” but hospital utilization metrics tied to resistance patterns and access:

Decision lever	What to monitor	Why it moves VABOMERE demand
Formulary access	New restrictive pathway adoption, prior authorization triggers, contract wins	Converts prescriptions into reimbursed use
Resistance mechanism fit	Local CRE enzyme composition (serine carbapenemases vs other mechanisms)	Determines whether vaborbactam provides clinical advantage
Stewardship rules	ICU and ID service approvals, restriction loosening or tightening	Governs volume more than label eligibility
Hospital mix	Growth in target-heavy facilities (ICUs, LTACH)	Increases addressable patient count
Competitive displacement	Utilization shifts to alternative BL-BLIs or newer agents	Impacts realized share within the same patient cohort

---

Key Takeaways

• VABOMERE is positioned as a meropenem + vaborbactam regimen designed for resistance-mechanism specific coverage in hospital infections tied to selected carbapenemases.
• A complete, citable clinical trials update and a numeric market projection cannot be produced from the information provided in the prompt.
• For decision-making, demand is primarily driven by stewardship/formulary access and alignment with local resistance mechanism prevalence.

---

FAQs

1. What makes VABOMERE different from other carbapenems?
   It combines meropenem with vaborbactam, a beta-lactamase inhibitor targeting serine carbapenemase mechanisms.

2. Which infection categories drive VABOMERE use?
   Hospital settings treat it for labeled bacterial pneumonia categories (HAP/VAP) and complicated urinary tract infections.

3. What most affects VABOMERE hospital volume?
   Restrictive formulary pathways, stewardship approvals, and local antibiogram alignment with the resistance mechanism it targets.

4. How do diagnostics change VABOMERE adoption?
   Rapid identification of pathogen and resistance mechanism increases the likelihood that clinicians choose the regimen aligned to that mechanism.

5. What is the biggest risk to VABOMERE market share?
   Competitive displacement when alternative BL-BLIs or newer agents better match the local resistance landscape or win formulary preference.

---

References (APA)

No sources were provided in the prompt, and no citable trial or market dataset is included.